Sunday, November 18, 2018
Redactor's Choice
You are here: Home / Tag: pfizer (page 3)

Tag: pfizer

Pfizer Completes Acquisition of Anacor

Pfizer_logo

“Now that Anacor is part of Pfizer, we can accelerate our shared commitment to help patients with inflammatory disease, an area of high unmet medical need,” said Albert Bourla, Group President, Pfizer Innovative Health. “We believe that Pfizer is in a position to quickly capitalize on the benefits offered by the combination with Anacor, including the potential for a near-term U.S. product launch and subsequent commercialization of crisaborole, a differentiated asset with compelling clinical data. If approved, crisaborole has the potential to be... Read More »

Pfizer Breaks Ground On New Biologics Clinical Manufacturing Facility In Andover, Massachusetts

Pfizer_logo

Pfizer’s Andover campus currently includes 7 buildings which house laboratories, clinical and commercial manufacturing suites, and support areas. It also includes a multiproduct manufacturing facility, which allows clinical and commercial products to be manufactured simultaneously, supporting a range of Pfizer product supply. The new clinical manufacturing facility is designed with 5 independent manufacturing suites to support Pfizer’s highly complex and diverse biologics research effort. The facility will: Employ flexible design to full... Read More »

Pfizer Announces FDA Advisory Committees’ Recommend ALO-02 (Oxycodone Hydrochloride And Naltrexone Hydrochloride) Extended-Release Capsules For Approval

pfizer

The Committees recommended the inclusion of abuse-deterrent labeling for intranasal (11 to 4) and intravenous (9 to 6) routes of abuse. They voted against inclusion of abuse-deterrent labeling for the oral route (6 to 9). The FDA will take the Committees’ recommendations into consideration before taking action on the New Drug Application for ALO-02. “Pfizer believes the ALO-02 data support approval with abuse-deterrent labeling and we look forward to ongoing discussions with the FDA,” said Ken Verburg, PhD, Chief Development Officer, Neurosc... Read More »

Pfizer Invites Public To Listen To Webcast Of Pfizer Discussion At Healthcare Conference

Pfizer_logo

To listen to the webcast, visit our web site at www.pfizer.com and click on the “UBS 2016 Global Healthcare Conference” link in the For Investors section located on the lower right-hand corner of that page. Information on accessing and pre-registering for the webcast will be available at www.pfizer.com beginning today. Visitors will be able to listen to an archived copy of the webcast at www.pfizer.com. ... Read More »

Bococizumab SPIRE-2 Cardiovascular Outcome Study Fully Enrolled

Pfizer logo 2013

Pfizer Inc. today announced patient enrollment completion in the global SPIRE-2 cardiovascular outcome trial for its investigational agent bococizumab. SPIRE-2 is evaluating the efficacy and safety of bococizumab compared to placebo in reducing the risk of major cardiovascular events among approximately 10,600 patients at high risk for cardiovascular disease - including those without a prior history of cardiovascular events – who are on highly-effective statins or with documented statin intolerance. The SPIRE-2 study is one of two cardiovasc... Read More »

CHANTIX®/CHAMPIX® (Varenicline) Results From The Largest Global Clinical Trial Of Smoking Cessation Medicines Published In The Lancet

Pfizer_logo

Pfizer Inc. today announced results published in The Lancet from the largest clinical trial of approved smoking cessation medicines, called EAGLES (Evaluating Adverse Events in a Global Smoking Cessation Study). This smoking cessation trial included 8,144 adult smokers and was designed to compare the neuropsychiatric safety of CHANTIX®/CHAMPIX® (varenicline) and bupropion with placebo and nicotine patch in adult smokers with and without a history of psychiatric disorders. The authors concluded that the trial did not show a significant increase ... Read More »

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Pfizer_logo

To listen to the webcast, visit our web site at www.pfizer.com and click on the “27th Annual Piper Jaffray Healthcare Conference” link in the For Investors section located on the lower right-hand corner of that page. Information on accessing and pre-registering for the webcast will be available at www.pfizer.com beginning today. Visitors will be able to listen to an archived copy of the webcast at www.pfizer.com. ... Read More »

Pfizer and the Avon foundation for women announce $1 million grants program to address gaps in support for people living with metastatic breast cancer

breast

The survey is the first of its kind to examine the general public’s understanding of metastatic breast cancer, which affects up to 250,000 women and men in the U.S. today.2 The survey results reveal widely held misperceptions about the causes, treatments and outcomes related to metastatic breast cancer, underscoring the need for better efforts to educate the public about the disease.1 To help encourage these efforts and drive greater support for people living with metastatic breast cancer and their caregivers, Pfizer and the Avon Foundation for... Read More »

Pfizer brings frequent heartburn relief over-the-counter with new Nexium® 24hr

heart2

Pfizer acquired exclusive global OTC rights to NEXIUM®, one of the largest selling prescription brands in the U.S., from AstraZeneca in August 2012. Nexium 24HR was approved by the Food and Drug Administration on March 28, and received three year market exclusivity. Switching medicines from prescription to non-prescription status improves consumer access to affordable healthcare options, empowers people to take charge of their health, and is an important strategy for Pfizer. The launch of Nexium 24HR makes Pfizer a leading player in all four of... Read More »

Pfizer announces detailed results for phase 3 opt retreatment study of tofacitinib in adults with moderate-to-severe chronic plaque psoriasis

doc

The first primary endpoint of OPT Retreatment evaluated the maintenance of clinical response in patients who remained on tofacitinib after an initial treatment phase compared to patients who were switched to placebo (withdrawal phase). The second primary endpoint examined patients who lost half of their original clinical response during the withdrawal phase, and measured the proportion of these patients who regained their original clinical response after restarting treatment with tofacitinib. Throughout the study, the efficacy response was meas... Read More »

Scroll To Top